South San Francisco, CA, September 16, 2024 – FlemingMartin is pleased to announce that Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycle therapies, has hired Clovis Célestin as Executive Director and Head of Information Technology.

Clovis is a seasoned IT professional with 30 years of experience across the function, serving both large and small companies. Over the past decade, during tenures with ChemoCentryx (acquired by Amgen), MyoKardia (acquired by BMS), and Portola Pharmaceuticals (acquired by Alexion), Clovis played a pivotal role in defining and executing transformational technology roadmaps during periods of rapid growth and change. Clovis is well-regarded for his entrepreneurial spirit, strong stakeholder management, crystal clear communication, and great passion for building and leading high-performing teams. Clovis earned a BSBA degree with a concentration in Management Information Systems from Suffolk University in Boston.

Circle Pharma Final Logo New Fc Circle Pharma is advancing the discovery and development of intrinsically cell-permeable macrocycles that can be delivered by multiple routes, including oral administration. Circle Pharma’s MXMO™ platform combines structure-based rational drug design and advanced synthetic chemistry to develop a new generation of macrocycle therapies for challenging targets to address unmet clinical needs.

FlemingMartin is a retained executive search firm focused on building exceptional teams in the Technology and Life Sciences sectors. We partner with CEOs, Boards, and Venture Capital as trusted advisors who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. Learn more at flemingmartin.com.